Jeannina Smith
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jeannina Smith has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
- Margaret R. Jorgenson
Department of Pharmacy University of Wisconsin Health Madison Wisconsin USA
7 shared publications - Christopher M. Saddler
Department of Medicine Division of Infectious Diseases University of Wisconsin School of Medicine and Public Health Madison Wisconsin USA
6 shared publications - Didier A. Mandelbrot
Division of Nephrology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin
5 shared publications - Angela Gifford
Department of Surgery, University of Wisconsin-Madison, 600 Highland Ave, Madison, WI 53792
4 shared publications - David H. O'COnnor
Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, Wisconsin, United States of America
4 shared publications - Jacqueline Garonzik-Wang
Department of Surgery, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, Alabama, USA; Comprehensive Transplant Institute, University of Alabama at Birmingham, Birmingham, Alabama, USA
4 shared publications
Latest Publications
- Open Access
A Case Report Describing a Persistent SARS-CoV-2 Infection Outcomes and Mutations Associated with B-cell Deficiency
Background: Immunocompromised (IC) individuals are at increased risk for persistent SARS-CoV-2 infections and can develop new viral mutations and lineages not seen in the community. In this case report, a persistent SARS-CoV-2 infection (330 days) in an IC patient is examined for viral mutations and mutations associated with cryptic lineages. Case Presentation: The patient was followed in a longitudinal study examining persistent SARS-CoV-2 in IC patients. The patient provided stool and nasal swab samples biweekly until 28 days post-enrollment, then monthly, and then quarterly after 12 month post enrollment until the participant was no longer positive for SARS-CoV-2. Staff performed RT-qPCR and viral sequencing on the samples. Viral mutations from the XBK lineage were already present in the initial sample. By the end of the infection period, there were 40 fixed consensus changes from XBK of which two mutations were typical for cryptic lineages. Mutations increased steadily over time, with most mutations fixed by day 253, including the cryptic typical mutations. Conclusion: This case demonstrates the potential for persistent SARS-CoV-2 infections to develop mutations and lineages in IC patients and highlights the need for continued SARS-CoV-2 monitoring and treatment in this vulnerable population.
Open AccessA Case Report Describing a Persistent SARS-CoV-2 Infection Outcomes and Mutations Associated with B-cell Deficiency
Background: Immunocompromised (IC) individuals are at increased risk for persistent SARS-CoV-2 infections and can develop new viral mutations and lineages not seen in the community. In this case report, a persistent SARS-CoV-2 infection (330 days) in an IC patient is examined for viral mutations and mutations associated with cryptic lineages. Case Presentation: The patient was followed in a longitudinal study examining persistent SARS-CoV-2 in IC patients. The patient provided stool and nasal swab samples biweekly until 28 days post-enrollment, then monthly, and then quarterly after 12 month post enrollment until the participant was no longer positive for SARS-CoV-2. Staff performed RT-qPCR and viral sequencing on the samples. Viral mutations from the XBK lineage were already present in the initial sample. By the end of the infection period, there were 40 fixed consensus changes from XBK of which two mutations were typical for cryptic lineages. Mutations increased steadily over time, with most mutations fixed by day 253, including the cryptic typical mutations. Conclusion: This case demonstrates the potential for persistent SARS-CoV-2 infections to develop mutations and lineages in IC patients and highlights the need for continued SARS-CoV-2 monitoring and treatment in this vulnerable population.
- Open Access
- 1 January 2026
- Published by Wiley in Case Reports in Infectious Diseases
- Vol. 2026 (1) , 6154094
Describing a Persistent SARS‐CoV‐2 Infection Outcomes and Mutations Associated With B‐Cell Deficiency: A Case Report
Background: Immunocompromised (IC) individuals are at an increased risk for persistent SARS‐CoV‐2 infections and can develop new viral mutations and lineages not seen in the community. In this case report, a persistent SARS‐CoV‐2 infection (330 days) in an IC patient is examined for viral mutations and mutations associated with cryptic lineages. Case Presentation: The patient was followed up in a longitudinal study examining persistent SARS‐CoV‐2 in IC patients. The patient provided stool and nasal swab samples biweekly until 28 days postenrollment, then monthly, and then quarterly after 12 months post enrollment until the participant was no longer positive for SARS‐CoV‐2. Staff performed RT‐qPCR and viral sequencing on the samples. Viral mutations from the XBK lineage were already present in the initial sample. By the end of the infection period, there were 40 fixed consensus changes from XBK of which two mutations were typical for cryptic lineages. Mutations increased steadily over time, with most mutations fixed by day 253, including the cryptic typical mutations. Conclusion: This case demonstrates the potential for persistent SARS‐CoV‐2 infections to develop mutations and lineages in IC patients and highlights the need for continued SARS‐CoV‐2 monitoring and treatment in this vulnerable population.
- 1 January 2026
- Published by Wiley in Case Reports in Infectious Diseases
- Vol. 2026 (1) , 6154094
Open AccessDescribing a Persistent SARS‐CoV‐2 Infection Outcomes and Mutations Associated With B‐Cell Deficiency: A Case Report
Background: Immunocompromised (IC) individuals are at an increased risk for persistent SARS‐CoV‐2 infections and can develop new viral mutations and lineages not seen in the community. In this case report, a persistent SARS‐CoV‐2 infection (330 days) in an IC patient is examined for viral mutations and mutations associated with cryptic lineages. Case Presentation: The patient was followed up in a longitudinal study examining persistent SARS‐CoV‐2 in IC patients. The patient provided stool and nasal swab samples biweekly until 28 days postenrollment, then monthly, and then quarterly after 12 months post enrollment until the participant was no longer positive for SARS‐CoV‐2. Staff performed RT‐qPCR and viral sequencing on the samples. Viral mutations from the XBK lineage were already present in the initial sample. By the end of the infection period, there were 40 fixed consensus changes from XBK of which two mutations were typical for cryptic lineages. Mutations increased steadily over time, with most mutations fixed by day 253, including the cryptic typical mutations. Conclusion: This case demonstrates the potential for persistent SARS‐CoV‐2 infections to develop mutations and lineages in IC patients and highlights the need for continued SARS‐CoV‐2 monitoring and treatment in this vulnerable population.
- 6 May 2025
- Published by Elsevier in Transplantation Proceedings
- Vol. 57 (5) , 922-930
Longitudinal Assessment of Solid Organ Transplant Recipients With SARS-CoV-2 Infection
- 6 May 2025
- Published by Elsevier in Transplantation Proceedings
- Vol. 57 (5) , 922-930
Longitudinal Assessment of Solid Organ Transplant Recipients With SARS-CoV-2 Infection
- Open Access
- 21 February 2025
- Published by Elsevier in CMI Communications
- Vol. 2 (2)
Histoplasmosis and blastomycosis: Progress and possibilities
- 21 February 2025
- Published by Elsevier in CMI Communications
- Vol. 2 (2)
Open AccessHistoplasmosis and blastomycosis: Progress and possibilities
- Open Access
Longitudinal Assessment of Solid Organ Transplant Recipients with SARS-CoV-2 Infection
Background: Compared to immunocompetent individuals, those who are immunocompromised, including solid organ transplant (SOT) recipients, have higher SARS-CoV-2-related morbidity and mortality. We determined the duration of SARS-CoV-2 RNA positivity to evaluate viral persistence in SOT recipients. Methods: This study prospectively followed SOT recipients who recently tested positive for SARS-CoV-2. The duration of viral RNA shedding in nasal swabs and stool samples was tracked, and viral genome sequencing was performed where possible. Persistent infection was defined as a positive nucleic acid amplification test (NAAT) for SARS-CoV-2 at 28 days or later after initial infection. This duration was chosen based on the CDC recommendation that immunocompromised individuals isolate for at least 20 days 1 , compared to 10 days for non-immunocompromised individuals. Results: Of 30 SOT recipients, 12 (40%) had SARS-CoV-2 RNA in nasal swabs or stool 28 or more days after the first positive SARS-CoV-2 test. IC-015 had high viral loads (Ct1 , compared to 10 days for non-immunocompromised individuals. In 12 of 30 SOT subjects, SARS-CoV-2 RNA was detected at or beyond 28 days post-detection (dpd), despite vaccination and antibody and/or antiviral treatment in most participants. Three subjects tested positive for SARS-CoV-2 RNA past 50 dpd. The CDC recommendation for 20 days of isolation may be insufficient for SOT recipients. Viral persistence in the setting of host immune suppression, coupled with exposure to antiviral treatments, raises concern about the selection of unusual viral variants. Visual
Open AccessLongitudinal Assessment of Solid Organ Transplant Recipients with SARS-CoV-2 Infection
Background: Compared to immunocompetent individuals, those who are immunocompromised, including solid organ transplant (SOT) recipients, have higher SARS-CoV-2-related morbidity and mortality. We determined the duration of SARS-CoV-2 RNA positivity to evaluate viral persistence in SOT recipients. Methods: This study prospectively followed SOT recipients who recently tested positive for SARS-CoV-2. The duration of viral RNA shedding in nasal swabs and stool samples was tracked, and viral genome sequencing was performed where possible. Persistent infection was defined as a positive nucleic acid amplification test (NAAT) for SARS-CoV-2 at 28 days or later after initial infection. This duration was chosen based on the CDC recommendation that immunocompromised individuals isolate for at least 20 days 1 , compared to 10 days for non-immunocompromised individuals. Results: Of 30 SOT recipients, 12 (40%) had SARS-CoV-2 RNA in nasal swabs or stool 28 or more days after the first positive SARS-CoV-2 test. IC-015 had high viral loads (Ct1 , compared to 10 days for non-immunocompromised individuals. In 12 of 30 SOT subjects, SARS-CoV-2 RNA was detected at or beyond 28 days post-detection (dpd), despite vaccination and antibody and/or antiviral treatment in most participants. Three subjects tested positive for SARS-CoV-2 RNA past 50 dpd. The CDC recommendation for 20 days of isolation may be insufficient for SOT recipients. Viral persistence in the setting of host immune suppression, coupled with exposure to antiviral treatments, raises concern about the selection of unusual viral variants. Visual
- Open Access
- 18 May 2024
- Published by Wiley in Transplant Infectious Disease
- Vol. 26 (3) , e14302
Infective endocarditis is rare in patients with hematologic malignancy and neutropenia
Background: Infective endocarditis (IE) is a serious complication of bloodstream infections (BSIs) that occurs at variable rates depending on the pathogen and clinical setting. There is a paucity of data describing the risk of IE in patients with hematologic malignancy who develop bacteremia while neutropenic.Methods: Adult patients on the hematology ward from January 2018 to December 2020 with hematologic malignancy and bacteremia were evaluated retrospectively for endocarditis by applying the 2023 Duke‐ISCVID criteria. Charts of possible cases were evaluated 90 days after the initial BSI for new infectious complications that could indicate missed IE. Descriptive statistics compared patients admitted for hematopoietic stem cell transplantation (HSCT) to those admitted for alternative reasons (non‐HSCT).Results: Among the 1005 positive blood cultures initially identified, there were 66 episodes in 65 patients with hematologic malignancy and at least grade 3 neutropenia for a mean duration of 11.4 days during their admission. Transthoracic echocardiography (TTE) was performed in 34.8% of BSIs, and transesophageal echocardiography (TEE) in 6.1%. There were no new infectious complications in possible cases 90 days after their initial BSI. No cases of endocarditis were identified.Conclusions: Endocarditis is rare amongst patients with hematologic malignancy, bacteremia, and neutropenia, and no cases were identified in this cohort. The use of routine TTE in this setting seems unwarranted, and the addition of TEE is unlikely to improve patient‐centered outcomes. image
- 18 May 2024
- Published by Wiley in Transplant Infectious Disease
- Vol. 26 (3) , e14302
Open AccessInfective endocarditis is rare in patients with hematologic malignancy and neutropenia
Background: Infective endocarditis (IE) is a serious complication of bloodstream infections (BSIs) that occurs at variable rates depending on the pathogen and clinical setting. There is a paucity of data describing the risk of IE in patients with hematologic malignancy who develop bacteremia while neutropenic.Methods: Adult patients on the hematology ward from January 2018 to December 2020 with hematologic malignancy and bacteremia were evaluated retrospectively for endocarditis by applying the 2023 Duke‐ISCVID criteria. Charts of possible cases were evaluated 90 days after the initial BSI for new infectious complications that could indicate missed IE. Descriptive statistics compared patients admitted for hematopoietic stem cell transplantation (HSCT) to those admitted for alternative reasons (non‐HSCT).Results: Among the 1005 positive blood cultures initially identified, there were 66 episodes in 65 patients with hematologic malignancy and at least grade 3 neutropenia for a mean duration of 11.4 days during their admission. Transthoracic echocardiography (TTE) was performed in 34.8% of BSIs, and transesophageal echocardiography (TEE) in 6.1%. There were no new infectious complications in possible cases 90 days after their initial BSI. No cases of endocarditis were identified.Conclusions: Endocarditis is rare amongst patients with hematologic malignancy, bacteremia, and neutropenia, and no cases were identified in this cohort. The use of routine TTE in this setting seems unwarranted, and the addition of TEE is unlikely to improve patient‐centered outcomes. image
- Open Access
- 2 May 2024
- Published by Wiley in Critical Care Research and Practice
- Vol. 2024, 1-9
Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection among Kidney Transplant Recipients: A Large Single-Center Experience
Background. Kidney transplant recipients (KTRs) are a vulnerable immunocompromised population at risk of severe COVID-19 disease and mortality after SARS-CoV-2 infection. We sought to characterize the post-infection sequelae in KTRs at our center. Methods. We studied all adult KTRs (with a functioning allograft) who had their first episode of SARS-CoV-2 infection between 04/2020 and 04/2022. Outcomes of interest included risk factors for hospitalization, all-cause mortality, COVID-19-related mortality, and allograft failure. Results. Of 979 KTRs with SARS-CoV-2 infection, 381 (39) were hospitalized. In the multivariate analysis, risk factors for hospitalization included advanced age/year (HR: 1.03, 95 CI: 1.021.04), male sex (HR: 1.29, 95 CI: 1.041.60), non-white race (HR: 1.48, 95 CI: 1.171.88), and diabetes as a cause of ESKD (HR: 1.77, 95 CI: 1.412.21). SARS-CoV-2 Vaccination was associated with decreased risk of hospitalization (HR: 0.73, 95 CI: 0.590.90), all-cause mortality (HR: 0.52, 95 CI: 0.370.74), and COVID-19-related mortality (HR: 0.47, 95 CI: 0.310.71) in the univariate and multivariate analyses. Risk factors for both all-cause and COVID-19-related mortality in the multivariate analyses included advanced age, hospitalization, and respiratory symptoms for hospital admission. Furthermore, additional risk factors for all-cause mortality in the multivariate analysis included being a non-white recipient and diabetes as a cause of ESKD, with being a recipient of a living donor as protective. Conclusions. Hospitalization due to COVID-19-associated symptoms is associated with increased mortality. Vaccination is a protective factor against hospitalization and mortality.
- 2 May 2024
- Published by Wiley in Critical Care Research and Practice
- Vol. 2024, 1-9
Open AccessSequelae of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection among Kidney Transplant Recipients: A Large Single-Center Experience
Background. Kidney transplant recipients (KTRs) are a vulnerable immunocompromised population at risk of severe COVID-19 disease and mortality after SARS-CoV-2 infection. We sought to characterize the post-infection sequelae in KTRs at our center. Methods. We studied all adult KTRs (with a functioning allograft) who had their first episode of SARS-CoV-2 infection between 04/2020 and 04/2022. Outcomes of interest included risk factors for hospitalization, all-cause mortality, COVID-19-related mortality, and allograft failure. Results. Of 979 KTRs with SARS-CoV-2 infection, 381 (39) were hospitalized. In the multivariate analysis, risk factors for hospitalization included advanced age/year (HR: 1.03, 95 CI: 1.021.04), male sex (HR: 1.29, 95 CI: 1.041.60), non-white race (HR: 1.48, 95 CI: 1.171.88), and diabetes as a cause of ESKD (HR: 1.77, 95 CI: 1.412.21). SARS-CoV-2 Vaccination was associated with decreased risk of hospitalization (HR: 0.73, 95 CI: 0.590.90), all-cause mortality (HR: 0.52, 95 CI: 0.370.74), and COVID-19-related mortality (HR: 0.47, 95 CI: 0.310.71) in the univariate and multivariate analyses. Risk factors for both all-cause and COVID-19-related mortality in the multivariate analyses included advanced age, hospitalization, and respiratory symptoms for hospital admission. Furthermore, additional risk factors for all-cause mortality in the multivariate analysis included being a non-white recipient and diabetes as a cause of ESKD, with being a recipient of a living donor as protective. Conclusions. Hospitalization due to COVID-19-associated symptoms is associated with increased mortality. Vaccination is a protective factor against hospitalization and mortality.
- 23 August 2022
- Published by Wiley in Transplant Infectious Disease
- Vol. 24 (6) , e13932
Myalgia in liver transplant recipients after receiving tixagevimab/cilgavimab for pre‐exposure prophylaxis of COVID‐19: A case series
- 23 August 2022
- Published by Wiley in Transplant Infectious Disease
- Vol. 24 (6) , e13932
Myalgia in liver transplant recipients after receiving tixagevimab/cilgavimab for pre‐exposure prophylaxis of COVID‐19: A case series
- 13 July 2022
- Published by Wiley in Transplant Infectious Disease
- Vol. 24 (4) , e13898
Risk factors for high level cytomegalovirus viremia in liver transplant recipients and associated outcomes
Purpose: To evaluate epidemiology, risk‐factors, and outcomes of high‐level (HL) cytomegalovirus (CMV) viremia in liver transplant recipients.Methods: Adult patients receiving a liver transplant between 1/1/2017 and 9/30/2020 were evaluated. Viral loads at University of Wisconsin Health Clinical Laboratories were required to allow for numerical comparison. Primary objective was incidence and outcomes of HL CMV viremia (viral‐load > 100 000 IU/ml). Secondary objective was to elucidate risk factors to allow targeted interventions.Results: Two hundred nine patients met inclusion criteria; 175 kept their graft for at least 240 days. Of these nine patients developed HL CMV, 28 developed low‐level (LL CMV, viral‐load 250–100 000 IU/ml), and 138 did not develop CMV viremia. When comparing these three groups via classic statistical methods time from transplant to viremia was similar (HL 158 ± 77 days, LL 150 ± 76 days). Clinical factors were also similar with the exception of donor seropositivity (HL 87.5%, LL 70.4%, No CMV 49.6%, p = 0.025). HL CMV was significantly associated with graft loss (p < 0.0001) on Kaplan–Meier analysis; graft loss in the LL CMV group did not differ from the no CMV group (p = 0.96).To allow valid assessment of risk factors in the total study population (n = 209), models of time‐varying covariates were used, and Cox proportional hazards ratios were calculated. In this analysis, HL CMV was associated with a significantly increased risk of graft loss (HR 5.6, p = 0.0016). When investigating risk factors associated with HL CMV, donor seropositivity significantly increased risk (HR 8.85, 95% CI 1.13–71.43, p = 0.038). Pretransplant total bilirubin (HR 1.04, 95% CI 0.998–1.07, p = 0.06) trended toward significance. Recipient seronegativity, liver disease, clinical and allocation model for end‐stage liver disease (MELD), transplant surgery duration, age, sex, induction immunosuppression, and maintenance immunosuppression were not significantly associated with development of HL CMV.Conclusion: HL CMV after liver transplant is uncommon but is associated with a significantly increased risk of graft loss that is not present in those patients who develop LL CMV or do not develop CMV viremia. Given these negative graft effects, CMV stewardship interventions targeting recipients of CMV seropositive allografts are warranted. Future larger scale studies evaluating the potential role of other factors in risk stratification are needed. image
- 13 July 2022
- Published by Wiley in Transplant Infectious Disease
- Vol. 24 (4) , e13898
Risk factors for high level cytomegalovirus viremia in liver transplant recipients and associated outcomes
Purpose: To evaluate epidemiology, risk‐factors, and outcomes of high‐level (HL) cytomegalovirus (CMV) viremia in liver transplant recipients.Methods: Adult patients receiving a liver transplant between 1/1/2017 and 9/30/2020 were evaluated. Viral loads at University of Wisconsin Health Clinical Laboratories were required to allow for numerical comparison. Primary objective was incidence and outcomes of HL CMV viremia (viral‐load > 100 000 IU/ml). Secondary objective was to elucidate risk factors to allow targeted interventions.Results: Two hundred nine patients met inclusion criteria; 175 kept their graft for at least 240 days. Of these nine patients developed HL CMV, 28 developed low‐level (LL CMV, viral‐load 250–100 000 IU/ml), and 138 did not develop CMV viremia. When comparing these three groups via classic statistical methods time from transplant to viremia was similar (HL 158 ± 77 days, LL 150 ± 76 days). Clinical factors were also similar with the exception of donor seropositivity (HL 87.5%, LL 70.4%, No CMV 49.6%, p = 0.025). HL CMV was significantly associated with graft loss (p < 0.0001) on Kaplan–Meier analysis; graft loss in the LL CMV group did not differ from the no CMV group (p = 0.96).To allow valid assessment of risk factors in the total study population (n = 209), models of time‐varying covariates were used, and Cox proportional hazards ratios were calculated. In this analysis, HL CMV was associated with a significantly increased risk of graft loss (HR 5.6, p = 0.0016). When investigating risk factors associated with HL CMV, donor seropositivity significantly increased risk (HR 8.85, 95% CI 1.13–71.43, p = 0.038). Pretransplant total bilirubin (HR 1.04, 95% CI 0.998–1.07, p = 0.06) trended toward significance. Recipient seronegativity, liver disease, clinical and allocation model for end‐stage liver disease (MELD), transplant surgery duration, age, sex, induction immunosuppression, and maintenance immunosuppression were not significantly associated with development of HL CMV.Conclusion: HL CMV after liver transplant is uncommon but is associated with a significantly increased risk of graft loss that is not present in those patients who develop LL CMV or do not develop CMV viremia. Given these negative graft effects, CMV stewardship interventions targeting recipients of CMV seropositive allografts are warranted. Future larger scale studies evaluating the potential role of other factors in risk stratification are needed. image
- 27 January 2022
- Published by Wiley in Transplant Infectious Disease
- Vol. 24 (2) , e13795
Belatacept may result in profound and persistent loss of cytomegalovirus‐specific cell‐mediated immunity: A case report
- 27 January 2022
- Published by Wiley in Transplant Infectious Disease
- Vol. 24 (2) , e13795
Belatacept may result in profound and persistent loss of cytomegalovirus‐specific cell‐mediated immunity: A case report